Sol-Gel Technologies

Sol-Gel Technologies

Sol-Gel Technologies was founded in 1997 by Alon Seri-Levy and a team of materials scientists in Ness Ziona, Israel. The firm originated as a drug-delivery platform company: its core insight was that sol-gel chemistry — a method for creating solid silica from liquid precursors at low temperatures — could encase active pharmaceutical ingredients in microscopic glass-like shells. This would allow formulators to combine otherwise incompatible ingredients, control release rates, and reduce irritation, all within a topical cream or gel. The company has never been a family office or allocator; it is a publicly traded specialty pharmaceutical firm focused solely on dermatology. The firm’s strategy hinges on licensing its encapsulated molecules rather than building a commercial sales force. Its two FDA-approved products — Epsolay (encapsulated benzoyl peroxide for rosacea) and Twyneo (encapsulated tretinoin and benzoyl peroxide for acne) — are both licensed to Galderma, the Swiss dermatology giant, which markets them globally. Sol-Gel earns milestone payments and royalties on net sales. Beyond these commercial-stage assets, the pipeline includes early-stage programs for palmoplantar pustulosis and other inflammatory skin conditions, all using the same silica-shell technology. The geographic footprint centers on the US and European prescription dermatology markets, accessed through Galderma’s distribution network. Sol-Gel employs a lean, R&D-heavy operating model; as of its 2025 annual report filing, the company had fewer than 50 employees, with the majority in scientific and regulatory roles. The firm has no adjacent investment vehicles, no family-office structure, and no broader asset-management ambitions — it is a single-purpose biotech that raised public equity (Nasdaq: SLGL) to fund clinical trials. In February 2025, Sol-Gel announced a repurchase of 5.1 million shares from minority holders in a tender offer at approximately $0.57 per share, consolidating ownership and reducing its public float (per the company, February 2025). What distinguishes Sol-Gel structurally is its identity as a platform-technology company masquerading as a specialty pharma firm. Unlike most dermatology biotechs, which license individual molecules from university labs, Sol-Gel owns the underlying encapsulation method and can generate new product candidates by pairing the silica matrix with existing off-patent drugs. That platform logic — plus the public-company structure that lets it return capital via buybacks — makes it more akin to a royalty-backed materials company than a conventional drug developer.